Regeneron Pharmaceuticals REGN Net Income
Net Income at other companies
Other financials
Where this comes from
Reported directly by Regeneron Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The official record: Regeneron Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Regeneron Pharmaceuticals's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Regeneron Pharmaceuticals's net income?
- Regeneron Pharmaceuticals (REGN) reported net income of $727.2M in Q1 2026.
- How has Regeneron Pharmaceuticals's net income changed year-over-year?
- Regeneron Pharmaceuticals's net income decreased by 10.1% year-over-year, from $808.7M to $727.2M.
- What is the long-term trend for Regeneron Pharmaceuticals's net income?
- Over 4 years (2021 to 2025), Regeneron Pharmaceuticals's net income has grown at a -13.6% compound annual growth rate (CAGR), from $8.08B to $4.5B.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.